Clinical trial
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
NCT00088374 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00088374 |
|---|---|
| Title | 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease |
| Official title | A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Von Hippel Lindau Disease and Renal Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hippel-Lindau Disease, Kidney Cancer |
| Intervention type | Drug |
| Interventions | 17 allylamino-17-demethoxygeldanamycin, 18 FDG (Fludeoxyglucose 18F), [15-O] H2O, EPL diluent |
| Enrollment | 9 |
| Start date | Jul 1, 2004 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Jul 26, 2004 |
| Last update posted | Jul 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: